Added successfully to RFQ list

Added successfully to compare list

Our clients

o2h discovery offers a broad gamut of biochemical, biophysical, and cell-based bioassay screening services for supporting drug discovery programs of our various collaborators. To augment these services, we have incorporated SPR-based assays (surface plasmon resonance) in our portfolio using state-of-the-art Biacore T200 system.

The Biacore T200 provides real-time, label-free, affinity and kinetic analysis for various types of biomolecular interactions with high sensitivity and accuracy. This system enables our team to deliver robust, high-quality data in a time-bound manner for the screening of small molecules, biologics and NBEs (novel biological entities) at any phase of drug development. We offer various project-tailored SPR solutions which include the following:

  • Fragment-based drug discovery (FBDD)
  • Small molecule drug discovery
  • Biotherapeutic drug discovery

                             SPR - Biacore

(o2h discovery – Biacore T200)

o2h biology capabilities

We accelerate time-to-market using diverse scientific teams with extensive academic and industry expertise, that are committed to resource efficiency, scientific excellence, and strategic collaborations. The expanding team of biologists in India collaborates seamlessly with the UK team to provide clients with the best solution in terms of speed, cost, and talent. o2h Biology has the infrastructure and expertise to conduct a wide range of biochemical, biophysical, and cellular assays against a wide range of target classes, including enzymes, GPCRs, and ion channels. To enable these assays, the Biology department has state-of-the-art facilities for in-vitro pharmacology services, including sophisticated liquid-handling and assay-detection systems. We are expanding our infrastructure pipeline with FLIPR penta, CytoFLEX flow cytometer, and the Integra Assist Plus liquid handler.

To know more about our biology services offering or to request our brochure, please reach out to us at discovery@o2h.com.

our team

Sunil

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

Sunil's Biography

Read more

Sunil Shah

CEO - o2h Ventures and Co-Founder - o2h discovery

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University


Connect on linkedin

prashant shah

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant's Biography

Read more

Prashant Shah

CEO - o2h discovery and Co-Founder - o2h group

Prashant is a serial entrepreneur in life sciences and tech in which one of those companies was acquired by a public company. He is currently active in seed investing (a portfolio of ~50 companies), product/IP development, services, and building lab/office infrastructure. The early career was with the Strategy group at Accenture. He has a BEng, an MSc, in which he worked on the Human Genome Program at the Sanger Centre, and an MPhil in Management from the Judge Institute. Prashant is also a General Partner in the o2h SEIS/EIS Human Health Funds.


Connect on linkedin

Andy Morley

Andy Morley

Chief Scientific Officer

Andy's Biography

Read more

Andy Morley

Chief Scientific Officer

Andy is a highly experienced and accomplished Medicinal Chemist with over 25 years of experience in major pharmaceutical companies such as Sanofi-Aventis and AstraZeneca. He has extensive experience across all phases of drug discovery and has played a key role in the development of five candidates that have reached clinical trials. Andy is a prolific author and inventor, with over 55 publications and patents to his name. Since 2013, he has been working full-time with o2h Limited, where he leads the scientific evaluation of investment opportunities and provides scientific support. He has also served as CSO for two early-stage collaborations within the o2h Ventures portfolio, demonstrating his ability to successfully guide drug discovery projects from concept to clinical development.


Connect on linkedin

Nilesh Dagia

Nilesh Dagia

Chief Special Projects Officer

Nilesh's Biography

Read more

Nilesh Dagia

Chief Special Projects Officer

Nilesh leads the global operations of o2h group covering a wide range of innovation led investment, life-science and technology businesses. He is also overseeing the development and execution of the new o2h discovery Shirish Research Centre in Ahmedabad, India. Prior to joining o2h group, Nilesh worked with Piramal Group in various capacities including as an Alliance Manager for a risk-share oncology-based collaboration with a US Big Pharma and has also worked as the Head of Biology in Piramal Discovery solutions. Nilesh obtained his Ph.D. from Ohio University and completed a post-doc in Immunology, Stem Cells and Regenerative Medicine at Harvard Medical School. He is the author and inventor of >30 life science patents and publications. He received the Young Scientist of India award from OPPI in 2010.


Connect on linkedin

o2h group launched revolutionary project management app for drug discovery

o2h group launched revolutionary project management app for drug discovery. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules.

the influencer biotech bootcamp

Hauxton House, Mill Scitech Park, Cambridge

The world’s first biotech bootcamp, including the quintet influencer community that is the creative force driving biotech.

View more

latest news

Read about some of the most recent developments including research collaborations at o2h discovery

speak to a member of our team

Contact Us